Drugs / ZE50-0134
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06708897 | Apr 2025 → Mar 2026 overdue | chronic lymphocytic leukemia/small lymphocytic lymphoma | Lomond Therapeutics Holdings, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06787131 | May 2024 → Jul 2025 | — | Lomond Therapeutics Holdings, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZE 50-0134 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06708897 ↗ |
| Route | Oral | “oral capsules QD” NCT06708897 ↗ |